keyword
https://read.qxmd.com/read/38822682/topical-glaucoma-medications-possible-implications-on-the-meibomian-glands
#1
REVIEW
Fredrik Fineide, Morten Magnø, Kristian Dahlø, Miriam Kolko, Steffen Heegaard, Jelle Vehof, Tor Paaske Utheim
One of the most common causes of blindness on a global scale is glaucoma. There is a strong association between glaucoma and increased intraocular pressure (IOP). Because of this, adequate IOP-lowering is the most important treatment strategy, mostly through topical eyedrops. Well-functioning meibomian glands are paramount for maintaining a stable tear film, and their dysfunction is the most common cause of dry eye disease. There is a growing concern that both topical glaucoma medications themselves and their added preservatives damage the meibomian glands, and consequently, the ocular surface...
June 1, 2024: Acta Ophthalmologica
https://read.qxmd.com/read/38802884/a-su6668-pure-nanoparticle-based-eyedrops-toward-its-high-drug-accumulation-and-long-time-treatment-for-corneal-neovascularization
#2
JOURNAL ARTICLE
Han Wu, Jinfa Ye, Minjie Zhang, Lingyu Zhang, Sijie Lin, Qingjian Li, Yanbo Liu, Yun Han, Caihong Huang, Yiming Wu, Yuhang Cheng, Shundong Cai, Lang Ke, Gang Liu, Wei Li, Chengchao Chu
Corneal neovascularization (CNV) is one of the common blinding factors worldwide, leading to reduced vision or even blindness. However, current treatments such as surgical intervention and anti-VEGF agent therapy still have some shortcomings or evoke some adverse effects. Recently, SU6668, an inhibitor targeting angiogenic tyrosine kinases, has demonstrated growth inhibition of neovascularization. But the hydrophobicity and low ocular bioavailability limit its application in cornea. Hereby, we proposed the preparation of SU6668 pure nanoparticles (NanoSU6668; size ~135 nm) using a super-stable pure-nanomedicine formulation technology (SPFT), which possessed uniform particle size and excellent aqueous dispersion at 1 mg/mL...
May 27, 2024: Journal of Nanobiotechnology
https://read.qxmd.com/read/38788970/development-of-inert-coatings-to-prevent-drug-retention-in-3d-printed-diffusion-cells
#3
JOURNAL ARTICLE
Carlos Bendicho-Lavilla, Victoria Díaz-Tomé, Iria Seoane-Viaño, Asteria M Luzardo-Álvarez, Francisco J Otero-Espinar
Diffusion cells play a crucial role in the pharmaceutical and cosmetic fields by assessing the release and permeation of active pharmaceutical ingredients across membranes. However, commercially available glass-based devices, such as Franz diffusion cells, are expensive and fragile. The emergence of three-dimensional (3D) printing technology enables the creation of diffusion cells with cost-effective polymeric materials and resins, offering exceptional precision and custom geometries. Nonetheless, there are challenges associated with interactions between 3D printing materials and drug molecules...
May 22, 2024: International Journal of Pharmaceutics
https://read.qxmd.com/read/38785065/the-effect-of-intense-pulsed-light-combined-with-topical-0-05-cyclosporin-a-eyedrops-in-the-treatment-of-sj%C3%A3-gren-s-syndrome-related-dry-eye
#4
JOURNAL ARTICLE
Yanan Huo, Xiaodan Huang, Lin Lin, Shuo Yang, Zhenwei Qin, Zhu Yirui, Yujie Mou, Xiuming Jin
OBJECTIVES: This study aimed to assess the effectiveness and safety of intense pulsed light (IPL) therapy plus topical 0.05% cyclosporine A (CsA) eye drops to treat Sjögren's Syndrome-related dry eyes (SS-DE). RESEARCH DESIGN AND METHODS: In this prospective, randomized trial included, 60 individuals with SS-DE symptoms were randomized to receive topical eye drops containing either 0.1% sodium hyaluronate (Group S) or 0.05% CsA (Group C) plus IPL therapy. Before the first treatment (baseline), and at 12, 16, and 20 weeks after treatment commencement, we assessed the best corrected visual acuity (BCVA), the Ocular Surface Disease Index (OSDI) score, the Schirmer I test (SIT), noninvasive tear breakup time (NBUT), corneal fluorescein staining (CFS), meibomian gland (MG) dropout, lid margin abnormality, MG expressibility, and meibum quality...
May 24, 2024: Expert Review of Clinical Immunology
https://read.qxmd.com/read/38766326/combinative-approach-of-transzonular-triamcinolone-moxifloxacin-and-perioperative-drops-to-minimize-postoperative-complications-of-cataract-surgery
#5
JOURNAL ARTICLE
Behnam Rabiee, Muhamad Festok, Michael Gaspari, Abid Haseeb, Aaila Chaudhry, Layla Kamoun, Imtiaz Chaudhry, Iftikhar Chaudhry
AIM: To investigate the effectiveness of combination therapy with transzonular triamcinolone-moxifloxacin and conventional perioperative drops in reducing postoperative complications of cataract surgery. METHODS: Electronic medical records of cataract surgery patients (single surgeon) were reviewed from January 2018 to September 2021. The rate of postoperative complications including prolonged and/or recurrent postoperative inflammation, endophthalmitis, cystoid macular edema (CME), and intraocular pressure (IOP) was compared between the patients receiving combinative therapy and patients receiving drops only...
2024: International Journal of Ophthalmology
https://read.qxmd.com/read/38745785/dry-eye-disease-symptoms-among-glaucoma-patients-at-a-portuguese-hospital
#6
JOURNAL ARTICLE
Catarina Pestana Aguiar, Pedro Teixeira, Inês Almeida, João Chibante-Pedro, Jeniffer Jesus
INTRODUCTION: Glaucoma-related dry eye disease (DED) is often underestimated, but it is an important comorbidity affecting 40% to 59% of glaucoma patients. It may be an exacerbation of a pre-existing condition or a novel disease starting after the initiation of topical medication. The cumulative effect of medication, preservatives and excipients leads to an alteration in tear film composition and ocular surface stability. The main purpose of this investigation was to study a group of Portuguese glaucoma patients regarding the presence of DED symptoms and correlate the severity of the symptoms with the usage of different types of glaucoma topical medications...
April 2024: Curēus
https://read.qxmd.com/read/38736523/a-cxcr3-activating-peptide-increases-tear-break-up-time-and-corrects-corneal-haze-in-a-rabbit-model-of-environmental-dry-eye
#7
JOURNAL ARTICLE
Alan Wells, Yadong Wang, Hanshuang Shao, Peri Sohnen, Shivalingappa K Swamynathan
PURPOSE: Environmentally-triggered dry eye disease (DED) or keratoconjunctivitis sicca (KCS), which constitutes the majority of DED cases, currently is palliatively treated with aqueous replacement solutions that do not target the dysfunction of the mucin and lipid components of tears. We tested whether a peptide that increased goblet cell numbers in a model of scleral chemical injury would also improve tear quality in environmental DED. METHODS: Environmental DED was established by exposing New Zealand white rabbits (8 per group, female) to 20% humidity with rapid air replacement and b...
2024: J Pharm Pharmacol Res
https://read.qxmd.com/read/38735502/integrated-high-throughput-drug-screening-microfluidic-system-for-comprehensive-ocular-toxicity-assessment
#8
JOURNAL ARTICLE
Kyongjin Cho, Jinho Lee, Jeongyun Kim
Traditional experimental methodologies suffer from a few limitations in the toxicological evaluation of the preservatives added to eye drops. In this study, we overcame these limitations by using a microfluidic device. We developed a microfluidic system featuring a gradient concentration generator for preservative dosage control with microvalves and micropumps, automatically regulated by a programmable Arduino board. This system facilitated the simultaneous toxicological evaluation of human corneal epithelial cells against eight different concentrations of preservatives, allowing for quadruplicate experiments in a single run...
May 10, 2024: Toxicology in Vitro: An International Journal Published in Association with BIBRA
https://read.qxmd.com/read/38709240/novel-effective-medical-therapy-for-acanthamoeba-keratitis
#9
JOURNAL ARTICLE
Antonio Di Zazzo, Chiara De Gregorio, Marco Coassin
PURPOSE: To report first clinical use of novel medical treatment for Acanthamoeba keratitis. METHODS: Interventional observational case series. Two patients with Acanthamoeba keratitis were unsuccessfully treated with polihexanide (PHMB) 0.02% and propamidine 0.1% for 6 weeks, then all were shifted in a compassionate use of PHMB 0.08% with novel standardized protocol. The postinterventional follow-up of patients was at least 7 months. RESULTS: PHMB 0...
May 1, 2024: Eye & Contact Lens
https://read.qxmd.com/read/38674593/topical-antibiotic-therapy-in-the-ocular-environment-the-benefits-of-using-moxifloxacin-eyedrops
#10
REVIEW
Lorenzo Drago
Moxifloxacin is a fourth-generation fluoroquinolone antibiotic available for ophthalmic use. It inhibits two enzymes involved in bacterial DNA synthesis, covering Gram-positive and Gram-negative pathogens. This spectrum allows for the formulation of self-preserving bottle solutions, while its interesting pharmacological profile is distinguished by efficacy at low tissue concentrations and by an infrequent dose regimen due to its long duration on ocular tissues. This enhances patient compliance, promoting its use in children...
March 25, 2024: Microorganisms
https://read.qxmd.com/read/38668163/recent-advances-in-nanotechnology-for-the-treatment-of-dry-eye-disease
#11
REVIEW
Giulia Coco, Giacinta Buffon, Andrea Taloni, Giuseppe Giannaccare
Dry eye disease (DED) incidence is continuously growing, positioning it to become an emergent health issue over the next few years. Several topical treatments are commonly used to treat DED; however, reports indicate that only a minor proportion of drug bioavailability is achieved by the majority of eye drops available on the market. In this context, enhancing drug ability to overcome ocular barriers and prolonging its residence time on the ocular surface represent a new challenge in the field of ocular carrier systems...
April 12, 2024: Nanomaterials
https://read.qxmd.com/read/38646409/pharmacologic-anisocoria-with-azelastine-the-importance-of-a-good-anamnesis
#12
Margarida Ribeiro, Rita Teixeira-Martins, Jorge Meira
Unilateral pharmacologic mydriasis is one of the differential diagnoses of anisocoria. This is a clinical case of a 37-year-old male patient admitted to the ophthalmology emergency department with unilateral mydriasis, an infrequent side effect of the antihistaminic drug azelastine. A comprehensive medical history including ocular medication was essential to avoid the need for additional tests and to exclude life-threatening conditions responsible for a similar presentation.
March 2024: Curēus
https://read.qxmd.com/read/38641196/dexamethasone-sodium-phosphate-loaded-nanoparticles-for-prevention-of-nitrogen-mustard-induced-corneal-injury
#13
JOURNAL ARTICLE
Sagun Poudel, Ehsan Kaffash, Long Zhao, Rudra Pangeni, Woon Nam Chow, Qingguo Xu
Nitrogen mustard (NM) is a potent vesicating chemical warfare agent that is primarily absorbed through skin, inhalation, or ocular surface. Ocular exposure of NM can cause acute to chronic keratopathy which can eventually lead to blindness. There is a current lack of effective countermeasures against ocular exposure of NM despite their imperative need. Herein, we aim to explore the sustained effect of Dexamethasone sodium phosphate (DSP)-loaded polymeric nanoparticles (PLGA-DSP-NP) following a single subconjunctival injection in the management and prevention of corneal injury progression upon exposure to NM...
April 17, 2024: Experimental Eye Research
https://read.qxmd.com/read/38625083/differential-impact-of-0-01-and-0-05-atropine-eyedrops-on-ocular-surface-in-young-adults
#14
RANDOMIZED CONTROLLED TRIAL
Yifan Luo, Ziang Yin, Jiali Zhang, Weijia Wang, Yingying Huang, Xue Li, Hao Chen, Fan Lu, Jinhua Bao
PURPOSE: To evaluate the effect of low-concentration (0.01% and 0.05%) atropine eyedrops on ocular surface characteristics in young adults. METHODS: Twenty-six myopic students aged 18 to 30 years were randomly assigned to receive either 0.01% or 0.05% atropine once nightly for 14 days, followed by cessation, with a ≥14-day interval between each administration. Assessments were conducted one, two, seven, and 14 days after using atropine with corresponding timepoints after atropine cessation...
April 2, 2024: Translational Vision Science & Technology
https://read.qxmd.com/read/38612500/retinal-neurodegeneration-in-an-intraocular-pressure-fluctuation-rat-model
#15
JOURNAL ARTICLE
Jeong-Sun Han, Chan Kee Park, Kyoung In Jung
Increased intraocular pressure (IOP) is the most important risk factor for glaucoma. The role of IOP fluctuation, independently from elevated IOP, has not yet been confirmed in glaucoma. We investigated the effects of IOP fluctuation itself on retinal neurodegeneration. Male rats were treated with IOP-lowering eyedrops (brinzolamide and latanoprost) on Mondays and Thursdays (in the irregular instillation group) or daily (in the regular instillation group), and saline was administered daily in the normal control group for 8 weeks...
March 26, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38594720/outcome-of-illuminated-microcatheter-assisted-circumferential-trabeculotomy-following-failed-angle-surgery-in-pax6-aniridic-glaucoma-a-case-report-and-literature-review
#16
JOURNAL ARTICLE
Tingyi Wu, Cui Cui, Yuanting Li, Ying Hong, Chun Zhang
BACKGROUND: Aniridia is a rare eye disorder with a high incidence of glaucoma, and surgical intervention is often needed to control the intraocular pressure (IOP). Here, we reported a case of illuminated microcatheter-assisted circumferential trabeculotomy (MAT) performed on an aniridic glaucoma patient following a previous failed angle surgery. The surgical procedures for aniridic glaucoma were also reviewed. CASE PRESENTATION: A 21-year-old man, diagnosed with aniridic glaucoma, came to our hospital consulting for the poor control of left eye's IOP despite receiving goniotomy surgery 3 years ago...
April 9, 2024: BMC Ophthalmology
https://read.qxmd.com/read/38540250/electroretinographical-analysis-of-the-effect-of-bgp-15-in-eyedrops-for-compensating-global-ischemia-reperfusion-in-the-eyes-of-sprague-dawley-rats
#17
JOURNAL ARTICLE
Barbara Takács, Anna Szilágyi, Dániel Priksz, Mariann Bombicz, Adrienn Mónika Szabó, Beáta Pelles-Taskó, Ágnes Rusznyák, Ádám Haimhoffer, Rudolf Gesztelyi, Zoltán Szilvássy, Béla Juhász, Balázs Varga
Retinal vascular diseases and consequential metabolic disturbances in the eye are major concerns for healthcare systems all around the world. BGP-15, a drug candidate small-molecule [O-(3-piperidino-2-hydroxy-1-propyl) nicotinic amidoxime dihydrochloride], has been formerly demonstrated by our workgroup to be retinoprotective both in the short and long term. Based on these results, the present study was performed to investigate the efficacy of BGP in an eyedrop formulation containing sulfobutylether-β-cyclodextrin (SBECD), which is a solubility enhancer as well...
March 13, 2024: Biomedicines
https://read.qxmd.com/read/38524465/novel-deliberately-sensitive-and-selective-tetrahydrozoline-voltammetric-sensors-integrated-with-a-copper-oxide-nanoparticle-zeolite-platform
#18
JOURNAL ARTICLE
Hana M Abumelha, Ali Sayqal, Razan M Snari, Kholood M Alkhamis, Arwa Alharbi, Zehbah A Al-Ahmed, Nashwa M El-Metwaly
The present study introduced a novel disposable screen-printed carbon electrodes (SPCEs) modified with copper oxide/zeolite nanostructures for eco-friendly selective differential pulse voltammetric quantification of tetrahydrozoline (THZ) in eyedrop samples and biological fluids. Modification of the electrode matrix with copper oxide nanoparticles/zeolite nanostructures (CuONPs/ZY) with their effective and synergistic electrocatalytic activity enhanced the electrode performance against electrooxidation of THZ at 0...
March 19, 2024: ACS Omega
https://read.qxmd.com/read/38492865/an-evaluation-of-the-efficacy-and-safety-of-timolol-maleate-0-5-microdrops-administered-with-the-nanodropper%C3%A2
#19
JOURNAL ARTICLE
Jennifer S Steger, Indira Durai, Annamalai Odayappan, Ramalakshmi Raman, Talla Sruthi, Allisa J Song, George Puthuran, Rengaraj Venkatesh, Elizabeth Colantuoni, Alan L Robin
OBJECTIVE OR PURPOSE: Examine if 12.5 μL timolol maleate 0.5% microdrops dispensed with the Nanodropper® Adaptor provide non-inferior intraocular pressure (IOP) reduction compared to conventional, 28 μL drops in open-angle glaucoma (OAG) and ocular hypertension (OHT) patients. DESIGN: Prospective, non-inferiority, parallel, multicenter, single-masked, active-controlled, randomized trial. SUBJECTS, PARTICIPANTS, AND/OR CONTROLS: Treatment-naïve subjects that were recently diagnosed with OAG/OHT at the Aravind Eye Care System...
March 14, 2024: Ophthalmology
https://read.qxmd.com/read/38481920/understanding-ocular-surface-disease-in-glaucoma-a-comparative-analysis-of-symptoms-and-objective-parameters
#20
JOURNAL ARTICLE
João Romano, Nélia Ferreira, Gonçalo Godinho, Rita Tomás, Nuno Oliveira, João Paulo Sousa
Background Glaucoma is a progressive optic neuropathy that may result in irreversible visual impairment and can diminish quality of life. Lowering intraocular pressure (IOP) through topical eyedrops is usually the primary approach to managing glaucoma. However, long-term treatment poses a risk to ocular surface health, leading to ocular surface disease (OSD). Preservative-containing eyedrops are implicated in OSD development due to their detrimental effects on the tear film and goblet cell density. OSD symptoms may impact patient compliance due to local side effects...
February 2024: Curēus
keyword
keyword
26346
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.